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Elevated Serum Bicarbonate Concentration in Chronic Kidney
Disease: A Call to Find the Cause
Zeid J. Khitan, MD
I n this issue, Dobre et al
1 reported an observational study
looking at results of annually measured serum bicarbonate
concentration in participants with chronic kidney disease
(CKD) enrolled in the Chronic Renal Insufficiency Cohort
(CRIC) using the marginal structural model, a validated
statistical method,2 to estimate the cumulative effect over
the period of the study and their effects on adjudicated heart
failure events, atherosclerotic events, renal disease progres-
sion, and mortality. In their analysis, they included patients
aged 21 to 74 years with estimated glomerular filtration rate
of 20 to 70 mL/min per 1.73 m2 and excluded patients with
NYHA Class III/IV heart failure. The final study population of
this analysis included 3586 participants. They adjusted all
models for age, gender, race/ethnicity, clinical center,
estimated glomerular filtration rate, proteinuria, diabetes,
systolic blood pressure, cardiovascular disease at baseline,
chronic obstructive pulmonary disease, tobacco use, diuretic
and alkali medication used, low-density lipoprotein, Fibroblast
growth factor-23 (FGF-23), and high-sensitivity C-reactive
protein. In their analysis, over an average of 6 years of follow-
up, they found a statistically significant higher rate of heart
failure events and mortality in participants who maintained
serum bicarbonate >26 mmol/L, while participants who
maintained serum bicarbonate <22 mmol/L had increased
risk of renal disease progression defined as halving of
estimated glomerular filtration rate or end-stage renal
disease. On the other hand, there was no association
between serum bicarbonate levels and atherosclerotic car-
diovascular events. In subgroup analysis, the relationship
between serum bicarbonate concentration and heart failure
and renal events was consistent across categories of race/
ethnicity, diabetes, or baseline kidney function. The strength
of association between serum bicarbonate >26 and <22 and
heart failure and renal events, respectively, persisted after
excluding participants taking alkali therapy, or who had
chronic obstructive pulmonary disease (COPD) or cardiovas-
cular disease at baseline. On the other hand, the study was
not powered to exclude participants on diuretic therapy (60%
of the study cohort were taking diuretics), which is a major
cause of metabolic alkalosis.
This observational study discusses a potential link between
acid–base abnormalities and cardiovascular and renal out-
come in a large cohort of patients with variable stages of CKD.
It adds to the existing literature an interesting observation
associating serum bicarbonate levels with outcome in this
patient population. It employed a novel statistical approach in
analyzing observational data that strengthen this association.
On the other hand, 2 factors need to be considered with
careful analysis of this study:
1. Besides bicarbonate, PCO2 is the second variable in the
Henderson-Hasselbalch equation that determines the acid–
base status. Although acid–base status can be predicted by
serum bicarbonate concentration alone in some individuals,
it might not be the case when examining a large cohort.
Current smokers were reported to be <15% in the CRIC
cohort, while >60% had a history of >100 cigarettes smoking
during their lifetime (ex-smokers). Moreover, spirometry
was not routinely used to diagnose COPD in this patient
population.3 Only 3.1% of all participants have a diagnosis of
COPD compared with >5% in the US general population.4
Considering all these factors, there seems to be a reason-
able chance that COPD (especially early with borderline
FEV1/FVC ratio <0.70) was underdiagnosed in this cohort.
In support of this trend, it has been shown that fewer than
half of the estimated 24 million Americans with airflow
obstruction have actually received a diagnosis of COPD.5 In
stable COPD, renal fluid retention and edema are enhanced
by hypercapnia-induced renal vasoconstriction and antidi-
uresis.6 Patients with edema due to chronic obstructive
pulmonary disease have severe retention of salt and water,
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reduction in renal blood flow and glomerular filtration, and
neurohormonal activation similar to that seen in patients
with edema due to myocardial disease.7 In isolated cat
kidneys, changes in PCO2 were inversely related to renal
blood flow and renal vascular resistance where doubling of
PCO2 decreased renal vascular resistance by 25% with
higher chance for salt and water retention.8 Giannoni et al
found increased sensitivity of chemoreceptors to both
hypoxia and hypercapnia in systolic heart failure patients—
a powerful and independent predictor of mortality. In the
early phase of heart failure syndrome, the chemoreceptors
may act in a compensatory way, triggering autonomic
nervous system changes in the cardiorespiratory system
that prevents tissue hypoxia or hypercapnia. However, over
time, chemoreceptor upregulation might promote a vicious
circle eliciting autonomic imbalance, neurohormonal acti-
vation, abnormal ventilatory responses, arrhythmias, and
favoring adverse events.9
2. Potassium abnormalities, especially hypokalemia, are
common and underestimated in patients with CKD.10,11
The use of diuretics is among the major causes in this
patient population. Sixty percent of participant in the CRIC
cohort were reported to be on diuretic therapy. In a large
cohort of 2500 patient with CKD, mostly stage 3 and 4,
hypokalemia (<4 mEq/L) was reported in over one third of
the participants. Moreover, hypokalemia was associated
with increased risk of end-stage renal disease in this CKD
population.11 In potassium-depletion metabolic alkalosis, a
high serum bicarbonate level is maintained by intracellular
acidosis in the renal tubular cells, with resulting increased
bicarbonate reabsorption at several sites along the
nephron. Moreover, pendrin, a luminal chloride-bicarbon-
ate exchanger, is reduced in potassium depletion.12
Therefore, hypokalemia is considered 1 major factor
commonly contributing to maintaining the state of meta-
bolic alkalosis. In a large cohort with heart failure and CKD
(estimated glomerular filtration rate <60 mL/min per
1.73 m2), hypokalemia was common (>20%) and associ-
ated with increased mortality and hospitalizations related
to heart failure and cardiovascular disease.10
Neurohormonal activation including the sympathetic ner-
vous system, the renin–angiotensin–aldosterone system, and
the antidiuretic hormone are beneficial in the short term in
patients with heart failure as they tend to restore cardiac output
and tissue perfusion toward normal. However, their deleterious
effects predominate over the long term. Drugs blocking the
sympathetic nervous system and the renin–angiotensin–aldo-
sterone system have been the mainstay of treating heart
failure. The relationship between hypokalemia and these
neurohormonal adaptive responses in heart failure is complex.
Hypokalemia or potassium depletion can result in elevation in
plasma renin activity13 and diminishes reuptake of norepineph-
rine by sympathetic nerve terminals.14 On the other hand and
adding to the complexity of this interaction, hypokalemia can be
the result of individual activation of these 2 systems.
Endogenous cardiotonic steroids, also known as digitalis-
like factors, natural inhibitors of the Na⁺/K⁺ ATPase, have
been postulated to play important roles in congestive heart
failure. This has been demonstrated in humans and rats by
resulting in lowering Na⁺/K⁺ ATPase activity.15,16 Moreover,
experimental data also indicate an association between
elevated plasma cardiotonic steroids and cardiovascular
remodeling. Ouabain, 1 member of the cardiotonic steroids
family, when infused to sustain physiologic concentrations,
induced myocardial hypertrophy in normotensive rats.17
Hypokalemia has been shown to potentiate the effect of
cardiotonic steroids in inducing left ventricular remodeling
and hypertrophy in in vitro and in vivo models.18–20
In conclusion, the association between elevated bicarbon-
ate concentration and heart failure exacerbation and mortality
in patients with CKD is real and alarming and should raise
questions in every patient with CKD. Hypokalemia and
respiratory acidosis should not be underestimated as they
can be a real threat to this patient population. Further research
is needed to take this important observation to a different level
and help substantially answer whether bicarbonate is a real
player or just a marker of neurohormonal activation.
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